XM does not provide services to residents of the United States of America.

Amplifon trims margin forecast as higher marketing costs weigh



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Amplifon trims margin forecast as higher marketing costs weigh</title></head><body>

Writes through with details on outlook, results and context

Oct 30 (Reuters) -Italian hearing aid company Amplifon AMPF.MI slightly lowered its annual margin guidance on Wednesday, after the metric was hit by higher marketing costs in Europe in the third quarter.

The company said it expected its recurring core profit margin to be broadly in line with 2023, when it posted a margin of 24%. It had previously forecast a margin of around 24.3% for this year.

Its third-quarter core profit margin was 20.3% of revenue, down 40 basis points from last year due to lower operating leverage and higher marketing investments to overcome market softness in the Europe, Middle East and Africa (EMEA) region.

Revenue grew 8% at constant exchange rates to 567.6 million euros ($613.75 million), driven by a 15.3% rise in the Americas, Amplifon's second biggest market that generates about 22% of its total sales.

Its biggest market, EMEA, saw slower 3.8% revenue growth due to a "still soft European market", Amplifon said.

"We continued along our revenue growth path thanks to an above-market organic performance and the significant contribution of acquisitions," CEO Enrico Vita said in the statement.

However, recurring net profit slumped 25.5% to 17.5 million euros due to increased financial expenses and higher depreciation and amortization following acquisitions.

Shares in Amplifon were down 2.9% at 1300 GMT, little changed from before the report was published.

Tech-driven competition in the hearing aid sector is intensifying after Switzeland's Sonova SOON.S launched a first-in-market hearing device utilising real-time AI, and Apple AAPL.O received U.S. approval for software that it said could transform its headphones into a personalized hearing aid.

Analysts have however said that Apple's move was not a concern for hearing aid players as over-the-counter devices target different population than prescription-based aids.

The Milan-based company confirmed its full-year revenue guidance for high single-digit percentage growth at constant exchange rates.

($1 = 0.9248 euros)



Reporting by Alberto Chiumento in Gdansk; editing by Milla Nissi

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.